DENVER, May 30, 2025 — In the last year, we’ve seen the first-ever FDA review of psychedelic-assisted therapy and state legislatures debating—and passing—bills to create legal access across the …
DENVER, May 29, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is bringing its International …
The MAPS community mourns the passing of Amanda Feilding — a towering figure in psychedelics, an unwavering advocate for cognitive liberty, and a dear friend to MAPS and our founder, Rick Doblin. Amanda …
DENVER, May 28, 2025 — Psychedelic Science – the premier global gathering for psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) …
The United States Sentencing Commission (USSC) had an opportunity during this most recent amendment cycle to make significant and meaningful changes to the Sentencing Guidelines that would at least begin …
April 15, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is bringing its International …
WCG IRB Canada certifies that the identified clinical trial complies with Good Clinical Practices as defined by the FDA, HHS, and ICH guidelines. The Research Ethics Board (REB) confirms its membership …
March 7, 2025 — Psychedelic Science — the premier global gathering for psychedelic research, medicine, policy, and culture hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS) …
Washington D.C.; February 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization that has led the psychedelic movement since 1986, has released …
FOR IMMEDIATE RELEASE: February 12, 2025 The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization that has led the psychedelic movement since 1986, today announced …
On January 15, 2025, MAPS submitted to the FDA the 2024 Cannabis Data Safety Update Report (DSUR) along with a protocol amendment. The DSUR serves as the FDA Annual Report on the progress of the drug …
FOR IMMEDIATE RELEASE: November 20, 2024 The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase …
